Literature DB >> 7284963

Significance of serum concentrations of carcinoembryonic antigen, ferritin, and calcitonin in breast cancer.

W Bezwoda, D Derman, T Bothwell, P MacPhil, J Levin, N De Moor.   

Abstract

Serum concentrations of carcinoembryonic antigen (CEA), ferritin, and calcitonin were measured in 107 patients with breast cancer, 80 of whom had overt or occult metastatic disease. CEA and ferritin values were statistically higher in those patients with metastases. In contrast, there was no correlation between calcitonin concentrations and the stage of the disease. All 27 subjects with CEA concentrations greater than 80 microgram/liter and 32 of 40 with values between 41-80 microgram/liter had metastatic disease. Ferritin was a definite but less sensitive discriminator, with metastatic disease present in all nine patients having concentrations greater than 400 microgram/liter. Such metastases were invariably hepatic. When the two measurements were used as a combined discriminant, the diagnostic accuracy increased somewhat. All 32 patients with CEA concentration greater than microgram/liter and/or a ferritin concentration greater than 400 microgram/liter had metastatic disease; the same was true for 32 of the 42 subjects with CEA concentration between 41-80 microgram/liter and/or a ferritin concentration between 200-400 microgram/liter. The measurements had prognostic value, both when assessed alone and together, with a median survival from the time of study significantly shorter in those with the highest values.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7284963     DOI: 10.1002/1097-0142(19811001)48:7<1623::aid-cncr2820480725>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Plasma ferritin determination as a diagnostic tool.

Authors:  C A Finch; V Bellotti; S Stray; D A Lipschitz; J D Cook; M J Pippard; H A Huebers
Journal:  West J Med       Date:  1986-11

2.  Axillary versus peripheral blood levels of sialic acid, ferritin, and CEA in patients with breast cancer.

Authors:  M Monti; S Catania; E Locatelli; R Gandini; A Reggiani; E Cunietti
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

3.  Tissue ferritin concentration and prognosis in carcinoma of the breast.

Authors:  R E Weinstein; B H Bond; B K Silberberg; C B Vaughn; P Subbaiah; D R Pieper
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

4.  Monitoring serum CEA in women with primary breast tumours positive for oestrogen receptor and with spread to lymph nodes.

Authors:  J C van der Linden; J P Baak; T Postma; J Lindeman; C J Meyer
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

Review 5.  Serum ferritin and malignant tumours.

Authors:  A Jacobs
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

6.  Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.

Authors:  M Stierer; H R Rosen; E Forster; C Moroz
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

7.  Prospective assessment of the role of five tumour markers in breast cancer.

Authors:  J F Robertson; D Pearson; M R Price; C Selby; J Pearson; R W Blamey; A Howell
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Metastatic breast cancer with constantly low CEA blood levels. A subgroup with unfavorable prognosis?

Authors:  G Krieger; H E Wander; M Kneba; M Prangen; G Bandlow; G A Nagel
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 9.  The detection and evaluation of human tumor metastases.

Authors:  D J Laurence; A M Neville
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  Objective measurement of therapeutic response in breast cancer using tumour markers.

Authors:  J F Robertson; D Pearson; M R Price; C Selby; R W Blamey; A Howell
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.